Baxter International Reports Q3 2025 Net Loss of $46 Million Amid Sales Growth

Baxter International Inc. reported its financial results for the third quarter of 2025, revealing a net loss attributable to stockholders of $46 million, or $(0.09) per diluted share, compared to a profit of $140 million, or $0.27 per diluted share, in the same period last year. For the nine months ended September 30, 2025, the company recorded a net income of $171 million, or $0.33 per diluted share, a significant recovery from a net loss of $137 million, or $(0.27) per diluted share, in the prior year. The results were impacted by special items that adversely affected net income by $401 million in the third quarter and $780 million year-to-date.

Total net sales for the third quarter increased by 5% to $2.835 billion, up from $2.699 billion in the prior year. The growth was driven by a 3% increase in U.S. sales, which reached $1.544 billion, and a 10% increase in sales from the rest of the world. The company attributed the sales growth to improved performance in its Medical Products & Therapies and Pharmaceuticals segments, despite challenges in the Healthcare Systems & Technologies segment, which saw a decline in operating income due to higher corporate cost allocations and increased expenses.

Baxter's strategic developments included the completion of the sale of its Kidney Care business to Carlyle Group for $3.8 billion in cash, finalized on January 31, 2025. This transaction has allowed the company to reduce its debt significantly, with $3.81 billion of short- and long-term indebtedness repaid using the net after-tax proceeds from the sale. The company is also undergoing restructuring efforts to optimize its operations following the divestiture, which includes a focus on cost management and efficiency improvements.

Operationally, Baxter reported a total employee headcount of approximately 50,000 as of September 30, 2025, reflecting ongoing adjustments in response to its strategic initiatives. The company continues to face challenges from supply chain disruptions, including those caused by Hurricane Helene, which impacted its North Cove facility. The facility has since resumed operations, but the company anticipates ongoing effects on demand for its intravenous solutions as customers adapt to fluid conservation practices.

Looking ahead, Baxter remains focused on enhancing its operational efficiency and navigating the complexities of the current economic environment, including inflationary pressures and geopolitical uncertainties. The company expects to continue leveraging its recent strategic actions to drive growth and improve profitability, while also managing the impacts of ongoing market conditions on its business performance.